"The approval of Onapgo (SPN-830) is a significant milestone in Parkinson’s disease management," Kelly Papesh, executive director of the Aossociation of Movement Disorder Advanced Practice ...

Onapgo is the first subcutaneous apomorphine infusion device approved to treat motor fluctuations in Parkinson’s disease. Onapgo reduced “off” time, as well as increased “good on” time ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl ...

Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine ...

Feb. 6. 2025 – The FDA has approved a new wearable device for adults with advanced Parkinson’s disease. Sold as Onapgo, this device gives a steady dose of apomorphine – a medicine that ...

For many, continuous treatment options like Onapgo can help to make days with Parkinson's more predictable." Approval of Onapgo was granted to Supernus Pharmaceuticals.

ONAPGO, a subcutaneous infusion device, treats motor fluctuations in advanced Parkinson's disease and launches in the U.S. in 2025. Supernus Pharmaceuticals has announced the FDA approval of ...

Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically ...

1 “ONAPGO represents a novel approach for adults with Parkinson’s disease who are experiencing motor fluctuations,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals.

Patients who received the Supernus treatment also experienced an increase in on time for their Parkinson’s medications — 2.8 hours for the Onapgo arm compared to 1.1 hours for the placebo group.